GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CG Oncology CGON · USD

Health Care · US listing · 🇺🇸 United States

Compare

74.74

-1.64%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CG Oncology

From its filings with the US Securities and Exchange Commission

SEC filings

CG Oncology is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CGON. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $4.0m and a net loss of $161.0m. At that date it held total assets of $791.6m and shareholders' equity of $752.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Jan 2024
Employees
142
Head office
3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Large accelerated filer

Leadership

Pay as last reported

  • Mr. Arthur KuanChairman of the Board, Chief Executive Officer, since 2017$11.2m
  • Mr. Ambaw BelletePresident, Chief Operating Officer$5.2m
  • Mr. Jim DeToreInterim Principal Financial and Accounting Officer
  • Mr. Robert LapetinaInterim Principal Financial and Accounting Officer
  • Mr. Joshua PattersonChief Compliance Officer, General Counsel and Secretary
  • Dr. Vijay KasturiChief Medical Officer
  • Dr. Leonard PostLead Independent Director$475,568
  • Ms. Christina RossiDirector
  • Ms. Susan GrafIndependent Director$455,895
  • Dr. Brian LiuIndependent Director$447,580
  • Dr. James MuleIndependent Director$437,158
  • Mr. Victor TongIndependent Director$444,301

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CG Oncology has a late-stage clinical biopharmaceutical focus on bladder cancer treatments.
  • Its lead candidate BOND-003 is in Phase II for BCG-unresponsive NMIBC disease.
  • The company's product portfolio includes PIVOT-006, a Phase III trial for adjuvant cretostimogene monotherapy.

Weaknesses

  • CG Oncology employs only 61 full-time employees as of the latest data.
  • The company's IPO occurred on 25 January 2024, indicating recent market entry.
  • Cretostimogene is currently in clinical development for NMIBC treatment.

Opportunities

  • The NMIBC market offers potential growth for bladder-sparing therapies like cretostimogene.
  • CG Oncology's BOND-003 Phase II trial could expand treatment options for BCG-unresponsive patients.
  • PIVOT-006 Phase III trial may lead to broader commercialization of cretostimogene.

Threats

  • BCG-unresponsive NMIBC patients face limited treatment options in the current market.
  • The biotechnology sector faces high regulatory hurdles for new drug approvals.
  • Clinical trials for cretostimogene may encounter delays or failures in development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.